3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
8
Melanoma
8
Pancreatic Neoplasms
7
Neoplasm Metastasis
5
Carcinoma, Non-Small-Cell Lung
5
Uterine Cervical Neoplasms
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Solid Tumor
2
Sarcoma
2
Recurrence
2
Liver Neoplasms
2
Glioblastoma
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Advanced Solid Tumor
2
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Solid Tumor, Adult
1
Salivary Gland Neoplasms
1
Refractory or Recurrent Solid Tumor
1
Pelvic Neoplasms
1
Ovarian Neoplasms
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Mesothelioma, Malignant
1
Interventions
Irinotecan
3
5,10-methylenetetrahydrofolic acid
2
tislelizumab
1
spartalizumab
1
repotrectinib
1
pralsetinib
1
palbociclib
1
encorafenib
1
Pemetrexed
1
Levoleucovorin
1
Leucovorin
1
KRN-330
1
Immune Checkpoint Inhibitors
1
Imatinib Mesylate
1
Gemcitabine
1
Flucytosine
1
Everolimus
1
Cisplatin
1
Cetuximab
1
Capecitabine
1
Ascorbic Acid
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Digestive System Neoplasms
×
spartalizumab
×
Clear all
NCT06022692
2023-09-05
HEAIS001
Zhejiang Hospital
Phase 1/2
Completed
18 enrolled